Welcome to our dedicated page for Allakos SEC filings (Ticker: ALLK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading a clinical-stage biotech filing can feel like decoding a lab notebook. Allakos’ 10-K spans hundreds of pages detailing Siglec-6 biology, trial cohorts, and burn-rate math—data critical yet difficult to sift through. If you have ever asked, “Where can I find Allakos’ quarterly earnings report 10-Q filing?” or “How do I track Allakos insider trading Form 4 transactions?”, you know the challenge.
Stock Titan turns that challenge into a quick scan. Our AI-powered summaries translate dense immunology and accounting notes into clear language, spotlighting pipeline updates, cash runway changes, and risk factors. Need the latest 8-K material events explained? We flag them in real time the moment they hit EDGAR. Curious about Allakos Form 4 insider transactions real-time? Instant alerts highlight executive stock moves before the market digests them. From the annual report 10-K simplified to a proxy statement executive compensation breakdown, every filing arrives with context you can understand.
Investors use this hub to:
- Monitor Allakos executive stock transactions Form 4 for buying or selling patterns
- Compare R&D spend quarter-over-quarter using Allakos earnings report filing analysis
- Stay ahead of trial milestones with Allakos 8-K material events explained
- Save hours understanding Allakos SEC filings explained simply
Whether you are underwriting dilution risk or just understanding Allakos SEC documents with AI, our platform delivers comprehensive coverage, expert commentary, and real-time updates—so you focus on decisions, not document hunts.
Schedule 13G/A filed on behalf of Beryl Capital entities and David A. Witkin reports no beneficial ownership of Allakos Inc. The filing, covering Common Stock (CUSIP 01671P100) and referencing the event date 06/30/2025, lists Beryl Capital Management LLC, Beryl Capital Management LP, Beryl Capital Partners II LP and David A. Witkin as reporting persons. Each reporting person disclaims beneficial ownership and the filing shows an aggregate amount of 0 shares (0%) for all listed filers. The document includes the issuer address, signatures dated 07/31/2025 by Andrew Nelson and David A. Witkin, a certification that the securities were acquired and held in the ordinary course of business and not to influence control, and Exhibit 99.1 (Agreement Regarding Joint Filing).
Three reporting persons filed a Schedule 13G/A for Allakos Inc. (Common Stock). The filers—Deep Track Capital, LP; Deep Track Biotechnology Master Fund, Ltd.; and David Kroin—report zero shares beneficially owned and 0.00% ownership of the class. The statement shows no sole or shared voting or dispositive power attributed to any reporting person.
The calculation of the percentage is based on the issuer's reported share count of 90,376,972 common shares outstanding. The filing includes a joint filing statement where the undersigned agree to file future amendments on behalf of each other and confirm responsibility for their respective disclosures.
FAQ
What is the current stock price of Allakos (ALLK)?
What is the market cap of Allakos (ALLK)?
